Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T34743
(Former ID: TTDS00213)
|
|||||
Target Name |
Bacterial Penicillin binding protein (Bact PBP)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 12 Target-related Diseases | + | ||||
1 | Acute bronchitis [ICD-11: CA42] | |||||
2 | Anaerobic bacterial infection [ICD-11: 1A00-1A09] | |||||
3 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
4 | Bronchitis [ICD-11: CA20] | |||||
5 | Glanders [ICD-11: 1B92] | |||||
6 | Gram-positive bacterial infection [ICD-11: 1B74-1F40] | |||||
7 | Mature B-cell lymphoma [ICD-11: 2A85] | |||||
8 | Myelodysplastic syndrome [ICD-11: 2A37] | |||||
9 | Respiratory infection [ICD-11: CA07-CA4Z] | |||||
10 | Rheumatoid arthritis [ICD-11: FA20] | |||||
11 | Sepsis [ICD-11: 1G40-1G41] | |||||
12 | Urinary tract infection [ICD-11: GC08] | |||||
Function |
Cell wall formation.
Click to Show/Hide
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 57 Approved Drugs | + | ||||
1 | Ampicillin | Drug Info | Approved | Bacterial infection | [2] | |
2 | Azlocillin | Drug Info | Approved | Pseudomonas infection | [3] | |
3 | Bacampicillin | Drug Info | Approved | Bacterial infection | [4] | |
4 | Balofloxacin | Drug Info | Approved | Gram-positive bacterial infection | [5] | |
5 | Carbenicillin | Drug Info | Approved | Infection of the upper and lower urinary tract | [3] | |
6 | Carbenicillin Indanyl Sodium | Drug Info | Approved | Bacterial infection | [3] | |
7 | Cefacetrile | Drug Info | Approved | Bacterial infection | [6] | |
8 | Cefaclor | Drug Info | Approved | Bacterial infection | [7] | |
9 | Cefadroxil | Drug Info | Approved | Bacterial infection | [8], [9] | |
10 | Cefamandole | Drug Info | Approved | Microorganisms infection | [3] | |
11 | Cefazolin | Drug Info | Approved | Bacterial infection | [10] | |
12 | Cefdinir | Drug Info | Approved | Bacterial infection | [11] | |
13 | Cefditoren | Drug Info | Approved | Bacterial infection | [12] | |
14 | Cefixime | Drug Info | Approved | Bacterial infection | [12] | |
15 | Cefonicid | Drug Info | Approved | Bacterial infection | [12] | |
16 | Cefoperazone | Drug Info | Approved | Bacterial infection | [12] | |
17 | Ceforanide | Drug Info | Approved | Bacterial infection | [12] | |
18 | Cefotetan | Drug Info | Approved | Bacterial infection | [12] | |
19 | Cefoxitin | Drug Info | Approved | Bacterial infection | [12] | |
20 | Cefpiramide | Drug Info | Approved | Bacterial infection | [12] | |
21 | Cefpodoxime | Drug Info | Approved | Bacterial infection | [12] | |
22 | Cefprozil | Drug Info | Approved | Bacterial infection | [12] | |
23 | Cefradine | Drug Info | Approved | Bacterial infection | [13], [14] | |
24 | Ceftazidime | Drug Info | Approved | Bacterial infection | [12] | |
25 | Ceftibuten | Drug Info | Approved | Chronic bronchitis | [3] | |
26 | Ceftizoxime | Drug Info | Approved | Bacterial infection | [12] | |
27 | Ceftriaxone | Drug Info | Approved | Bacterial infection | [15], [16] | |
28 | Cefuroxime | Drug Info | Approved | Acute bronchitis | [3] | |
29 | Cephalexin | Drug Info | Approved | Bacterial infection | [17], [18] | |
30 | Cephaloglycin | Drug Info | Approved | Bacterial infection | [19] | |
31 | Cephalothin Sodium | Drug Info | Approved | Bacterial infection | [3] | |
32 | Cephapirin | Drug Info | Approved | Sepsis | [3], [20] | |
33 | Ciprofloxacin XR | Drug Info | Approved | Bacterial infection | [3] | |
34 | Clofarabine | Drug Info | Approved | Acute lymphoblastic leukaemia | [3], [12], [21], [22] | |
35 | Cloxacillin | Drug Info | Approved | Bacterial infection | [23] | |
36 | Cyclacillin | Drug Info | Approved | Bacterial infection | [24], [3], [25] | |
37 | Dicloxacillin | Drug Info | Approved | Bacterial infection | [26] | |
38 | Ertapenem | Drug Info | Approved | Bacterial infection | [12] | |
39 | Flucloxacillin | Drug Info | Approved | Bacterial infection | [27] | |
40 | Hetacillin | Drug Info | Approved | Bacterial infection | [3] | |
41 | Loracarbef | Drug Info | Approved | Bacterial infection | [12] | |
42 | Meropenem | Drug Info | Approved | Bacterial infection | [12] | |
43 | Meticillin | Drug Info | Approved | Bacterial infection | [28] | |
44 | Nafcillin | Drug Info | Approved | Arthritis | [29], [3] | |
45 | Oxacillin | Drug Info | Approved | Bacterial infection | [30] | |
46 | Penicillin | Drug Info | Approved | Bacterial infection | [31] | |
47 | Penicillin G Benzathine | Drug Info | Approved | Bacterial infection | [3] | |
48 | Penicillin G Procaine | Drug Info | Approved | Bacterial infection | [3] | |
49 | Penicillin G Sodium | Drug Info | Approved | Bacterial infection | [3] | |
50 | Penicillin V | Drug Info | Approved | Bacterial infection | [16] | |
51 | Penicillin V Potassium | Drug Info | Approved | Bacterial infection | [3] | |
52 | Piperacillin | Drug Info | Approved | Bacterial infection | [32] | |
53 | Pivampicillin | Drug Info | Approved | Bacterial infection | [33] | |
54 | Pivmecillinam | Drug Info | Approved | Urinary tract infection | [34], [3] | |
55 | Tebipenem pivoxil | Drug Info | Approved | Respiratory tract infection | [35] | |
56 | Ticarcillin | Drug Info | Approved | Bacterial infection | [36] | |
57 | Ceftolozane sulfate | Drug Info | Phase 4 | Respiratory tract infection | [37] | |
Clinical Trial Drug(s) | [+] 8 Clinical Trial Drugs | + | ||||
1 | Cefluprenam | Drug Info | Phase 3 | Bacterial infection | [38] | |
2 | Ceftobiprole | Drug Info | Phase 3 | Community-acquired pneumonia | [39] | |
3 | Ceftobiprole medocaril | Drug Info | Phase 3 | Skin and skin-structure infection | [40] | |
4 | Sulopenem | Drug Info | Phase 3 | Urinary tract infection | [41] | |
5 | BOS-228 | Drug Info | Phase 2 | Bacterial infection | [42] | |
6 | Lenapenem hydrochloride hydrate | Drug Info | Phase 2 | Bacterial infection | [43] | |
7 | BAL-30072 | Drug Info | Phase 1 | Bacterial infection | [44] | |
8 | DZ-2640 | Drug Info | Phase 1 | Bacterial infection | [45] | |
Discontinued Drug(s) | [+] 14 Discontinued Drugs | + | ||||
1 | CEFCANEL DALOXATE HYDROCHLORIDE | Drug Info | Discontinued in Phase 3 | Bacterial infection | [46] | |
2 | CEFETECOL | Drug Info | Discontinued in Phase 3 | Bacterial infection | [47] | |
3 | Sanfetrinem | Drug Info | Discontinued in Phase 3 | Bacterial infection | [48] | |
4 | KP-736 | Drug Info | Discontinued in Phase 2 | Bacterial infection | [49] | |
5 | PA-1806 | Drug Info | Discontinued in Phase 2 | Bacterial infection | [50] | |
6 | Tomopenem | Drug Info | Discontinued in Phase 2 | Bacterial infection | [51] | |
7 | BRL-44154 | Drug Info | Discontinued in Phase 1 | Bacterial infection | [52] | |
8 | Cefdaloxime pentexil tosilate | Drug Info | Discontinued in Phase 1 | Bacterial infection | [53] | |
9 | CEFTRAZONAL BOPENTIL | Drug Info | Discontinued in Phase 1 | Bacterial infection | [54] | |
10 | DU-6681 | Drug Info | Discontinued in Phase 1 | Bacterial infection | [55] | |
11 | ER-35786 | Drug Info | Discontinued in Phase 1 | Bacterial infection | [56] | |
12 | FK-041 | Drug Info | Discontinued in Phase 1 | Bacterial infection | [57] | |
13 | MC-02,479 | Drug Info | Discontinued in Phase 1 | Bacterial infection | [58] | |
14 | BK-218 | Drug Info | Terminated | Bacterial infection | [59] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Binder | [+] 44 Binder drugs | + | ||||
1 | Ampicillin | Drug Info | [60] | |||
2 | Azlocillin | Drug Info | [61] | |||
3 | Bacampicillin | Drug Info | [62] | |||
4 | Carbenicillin | Drug Info | [63] | |||
5 | Cefacetrile | Drug Info | [65] | |||
6 | Cefaclor | Drug Info | [66] | |||
7 | Cefadroxil | Drug Info | [67] | |||
8 | Cefamandole | Drug Info | [68] | |||
9 | Cefazolin | Drug Info | [69] | |||
10 | Cefdinir | Drug Info | [70] | |||
11 | Cefditoren | Drug Info | [71] | |||
12 | Cefixime | Drug Info | [72] | |||
13 | Cefonicid | Drug Info | [73] | |||
14 | Cefoperazone | Drug Info | [74] | |||
15 | Ceforanide | Drug Info | [75] | |||
16 | Cefotetan | Drug Info | [76] | |||
17 | Cefoxitin | Drug Info | [77] | |||
18 | Cefpiramide | Drug Info | [62] | |||
19 | Cefpodoxime | Drug Info | [78] | |||
20 | Cefprozil | Drug Info | [79] | |||
21 | Cefradine | Drug Info | [77] | |||
22 | Ceftazidime | Drug Info | [80] | |||
23 | Ceftibuten | Drug Info | [81] | |||
24 | Ceftizoxime | Drug Info | [1] | |||
25 | Cefuroxime | Drug Info | [83] | |||
26 | Cephalexin | Drug Info | [84] | |||
27 | Cephapirin | Drug Info | [85] | |||
28 | Clofarabine | Drug Info | [86] | |||
29 | Cloxacillin | Drug Info | [87] | |||
30 | Cyclacillin | Drug Info | [62] | |||
31 | Dicloxacillin | Drug Info | [88] | |||
32 | Ertapenem | Drug Info | [1] | |||
33 | Flucloxacillin | Drug Info | [88] | |||
34 | Loracarbef | Drug Info | [78] | |||
35 | Meticillin | Drug Info | [90] | |||
36 | Nafcillin | Drug Info | [91] | |||
37 | Oxacillin | Drug Info | [92] | |||
38 | Penicillin V | Drug Info | [94] | |||
39 | Piperacillin | Drug Info | [95] | |||
40 | Pivampicillin | Drug Info | [62] | |||
41 | Pivmecillinam | Drug Info | [96] | |||
42 | Tebipenem pivoxil | Drug Info | [97] | |||
43 | Ticarcillin | Drug Info | [98] | |||
44 | Ceftobiprole medocaril | Drug Info | [102] | |||
Inhibitor | [+] 11 Inhibitor drugs | + | ||||
1 | Balofloxacin | Drug Info | [5] | |||
2 | Ciprofloxacin XR | Drug Info | [5] | |||
3 | Cefluprenam | Drug Info | [100] | |||
4 | BOS-228 | Drug Info | [42] | |||
5 | Lenapenem hydrochloride hydrate | Drug Info | [104] | |||
6 | BAL-30072 | Drug Info | [105] | |||
7 | CEFTRAZONAL BOPENTIL | Drug Info | [115] | |||
8 | ER-35786 | Drug Info | [117] | |||
9 | FK-041 | Drug Info | [118] | |||
10 | MC-02,479 | Drug Info | [119] | |||
11 | BK-218 | Drug Info | [120] | |||
Modulator | [+] 26 Modulator drugs | + | ||||
1 | Carbenicillin Indanyl Sodium | Drug Info | [64] | |||
2 | Ceftriaxone | Drug Info | [82] | |||
3 | Cephaloglycin | Drug Info | [82] | |||
4 | Cephalothin Sodium | Drug Info | [82] | |||
5 | Hetacillin | Drug Info | [89] | |||
6 | Meropenem | Drug Info | [82] | |||
7 | Penicillin | Drug Info | [93] | |||
8 | Penicillin G Benzathine | Drug Info | [93] | |||
9 | Penicillin G Procaine | Drug Info | [93] | |||
10 | Penicillin G Sodium | Drug Info | [93] | |||
11 | Penicillin V Potassium | Drug Info | [82] | |||
12 | Ceftolozane sulfate | Drug Info | [99] | |||
13 | Ceftobiprole | Drug Info | [101] | |||
14 | Sulopenem | Drug Info | [103] | |||
15 | DZ-2640 | Drug Info | [106] | |||
16 | CEFCANEL DALOXATE HYDROCHLORIDE | Drug Info | [107] | |||
17 | CEFETECOL | Drug Info | [108] | |||
18 | Sanfetrinem | Drug Info | [109] | |||
19 | KP-736 | Drug Info | [110] | |||
20 | PA-1806 | Drug Info | [111] | |||
21 | Tomopenem | Drug Info | [112] | |||
22 | BRL-44154 | Drug Info | [113] | |||
23 | Cefdaloxime pentexil tosilate | Drug Info | [114] | |||
24 | DU-6681 | Drug Info | [116] | |||
25 | RO 244383 | Drug Info | [124] | |||
26 | Sanfetrinem cilexetil | Drug Info | [109] |
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. | |||||
REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936. | |||||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 4 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050520. | |||||
REF 5 | Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. | |||||
REF 6 | Drug information of Cefacetrile, 2008. eduDrugs. | |||||
REF 7 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062206. | |||||
REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4831). | |||||
REF 9 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062291. | |||||
REF 10 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065244. | |||||
REF 11 | Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. | |||||
REF 12 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 13 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4830). | |||||
REF 14 | Textbook of Therapeutics: Drug and Disease Management. 2006, P892. By Richard A. Helms, Eric T. Herfindal, David J. Quan, Dick R. Gourley. | |||||
REF 15 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326). | |||||
REF 16 | How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. | |||||
REF 17 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4832). | |||||
REF 18 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061969. | |||||
REF 19 | Drug information of Cephaloglycin, 2008. eduDrugs. | |||||
REF 20 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062720. | |||||
REF 21 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802). | |||||
REF 22 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | |||||
REF 23 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061454. | |||||
REF 24 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4817). | |||||
REF 25 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062895. | |||||
REF 26 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062286. | |||||
REF 27 | Drug information of Flucloxacillin, 2008. eduDrugs. | |||||
REF 28 | Drug information of Meticillin, 2008. eduDrugs. | |||||
REF 29 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062527. | |||||
REF 30 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061490. | |||||
REF 31 | ClinicalTrials.gov (NCT00363688) Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin. U.S. National Institutes of Health. | |||||
REF 32 | Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag. 2008 Apr;4(2):303-14. | |||||
REF 33 | Drug information of Pivampicillin, 2008. eduDrugs. | |||||
REF 34 | Drug information of Pivmecillinam, 2008. eduDrugs. | |||||
REF 35 | Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00603-19. | |||||
REF 36 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050497. | |||||
REF 37 | ClinicalTrials.gov (NCT02421120) Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients. U.S. National Institutes of Health. | |||||
REF 38 | Usefulness of 7 day therapy with cefluprenam in the management of respiratory tract infections. Kansenshogaku Zasshi. 1997 Aug;71(8):770-87. | |||||
REF 39 | ClinicalTrials.gov (NCT03439124) Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia. U.S. National Institutes of Health. | |||||
REF 40 | ClinicalTrials.gov (NCT03137173) Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health. | |||||
REF 41 | ClinicalTrials.gov (NCT03357614) Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults. U.S. National Institutes of Health. | |||||
REF 42 | Clinical pipeline report, company report or official report of Boston Pharmaceuticals. | |||||
REF 43 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002282) | |||||
REF 44 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032341) | |||||
REF 45 | Pharmacokinetics and safety of ascending single doses of DZ-2640, a new oral carbapenem antibiotic, administered to healthy Japanese subjects. Antimicrob Agents Chemother. 2000 Mar;44(3):578-82. | |||||
REF 46 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002619) | |||||
REF 47 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000482) | |||||
REF 48 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002101) | |||||
REF 49 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000467) | |||||
REF 50 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011023) | |||||
REF 51 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014654) | |||||
REF 52 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005339) | |||||
REF 53 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003956) | |||||
REF 54 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002807) | |||||
REF 55 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006219) | |||||
REF 56 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005932) | |||||
REF 57 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007635) | |||||
REF 58 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009332) | |||||
REF 59 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000460) | |||||
REF 60 | Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80. | |||||
REF 61 | Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8. | |||||
REF 62 | Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. | |||||
REF 63 | Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. | |||||
REF 64 | Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61. | |||||
REF 65 | Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42. | |||||
REF 66 | Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74. | |||||
REF 67 | Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32. | |||||
REF 68 | The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54. | |||||
REF 69 | Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9. | |||||
REF 70 | Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60. | |||||
REF 71 | Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. | |||||
REF 72 | Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51. | |||||
REF 73 | Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6. | |||||
REF 74 | Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. | |||||
REF 75 | The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3. | |||||
REF 76 | In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. | |||||
REF 77 | Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. | |||||
REF 78 | Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. | |||||
REF 79 | Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8. | |||||
REF 80 | New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41. | |||||
REF 81 | Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. | |||||
REF 82 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 83 | Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30. | |||||
REF 84 | Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21. | |||||
REF 85 | The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85. | |||||
REF 86 | Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. | |||||
REF 87 | Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303. | |||||
REF 88 | Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. | |||||
REF 89 | JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051. | |||||
REF 90 | A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58. | |||||
REF 91 | Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10. | |||||
REF 92 | Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8. | |||||
REF 93 | Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model | |||||
REF 94 | Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40. | |||||
REF 95 | In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6. | |||||
REF 96 | Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7. | |||||
REF 97 | In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18. | |||||
REF 98 | Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7. | |||||
REF 99 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 100 | Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7. | |||||
REF 101 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. | |||||
REF 102 | Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509. | |||||
REF 103 | In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37. | |||||
REF 104 | Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42. | |||||
REF 105 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302. | |||||
REF 106 | In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8. | |||||
REF 107 | Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8. | |||||
REF 108 | Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1991 Jan;35(1):14-9. | |||||
REF 109 | Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae | |||||
REF 110 | In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother. 1991 Jan;35(1):104-10. | |||||
REF 111 | Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother. 1997 May;41(5):1010-6. | |||||
REF 112 | Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.Antimicrob Agents Chemother.2009 Mar;53(3):1238-41. | |||||
REF 113 | Can beta-lactams be re-engineered to beat MRSA . Clinical Microbiology and Infection Volume 12, Issue Supplement s2, pages 11-16, April 2006. | |||||
REF 114 | Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter. 2006 Mar;19(1):39-44. | |||||
REF 115 | Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):946-9. | |||||
REF 116 | Pharmacokinetics and Safety of Ascending Single Doses of DZ-2640, a New Oral Carbapenem Antibiotic, Administered to Healthy Japanese Subjects. Antimicrob Agents Chemother. 2000 March; 44(3): 578-582. | |||||
REF 117 | In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997 Feb;41(2):298-307. | |||||
REF 118 | In vitro antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo). 1999 Jul;52(7):649-59. | |||||
REF 119 | RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal be... Antimicrob Agents Chemother. 2003 Feb;47(2):658-64. | |||||
REF 120 | In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrob Agents Chemother. 1990 Feb;34(2):349-54. | |||||
REF 121 | Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity. Biochemistry. 1994 Nov 22;33(46):13593-610. | |||||
REF 122 | DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+. Mol Pharmacol. 1998 May;53(5):846-55. | |||||
REF 123 | Naphthyridinomycin-DNA adducts: a molecular modeling study. J Antibiot (Tokyo). 1991 Aug;44(8):885-94. | |||||
REF 124 | Mechanisms of resistance to cephalosporin antibiotics.Drugs.1987;34 Suppl 2:64-88. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.